NCT01841697View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)

PHASE3CompletedINTERVENTIONAL
Enrollment

642

Participants

Timeline

Start Date

June 13, 2013

Primary Completion Date

November 17, 2014

Study Completion Date

November 17, 2014

Conditions
Type 2 Diabetes
Interventions
DRUG

Omarigliptin

Omarigliptin (MK-3102) 25 mg oral capsule once a week for 24 weeks

DRUG

Sitagliptin

Sitagliptin 100 mg oral tablet once a day for 24 weeks

DRUG

Placebo to omarigliptin

Placebo to omarigliptin 25 mg oral capsule once a week for 24 weeks

DRUG

Placebo to Sitagliptin

Placebo to sitagliptin 100 mg oral tablet once a day for 24 weeks

DRUG

Open-label Metformin

Metformin oral tablet(s) - total daily dose of ≥1500 mg, once or twice a day

DRUG

Open-label Glimepiride

Glimepiride oral tablet(s) - total daily dose of 1 to 6 mg once a day as rescue therapy

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01841697 - Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026) | Biotech Hunter | Biotech Hunter